About Lophius Biosciences
Lophius Biosciences is a Healthcare company based in Regensburg (Germany) founded in 2008. T-cell-based diagnostics for infectious and immune diseases are developed. Lophius Biosciences has raised $23.73 million across 9 funding rounds from investors including European Union, VRD and Bayern Kapital. The company has 28 employees. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and Diversified. Its legal entity is Lophius Biosciences GmbH.
Company details
Develops T-cell-based diagnostics for infectious and immune diseases. It has two proprietary platforms, T-activation Technology which allows the detection of clinically relevant effector cells such as T helper, NK, NKT-like, and CTL cells,and Reverse T cell Technology (RTT) which detects pathogen-specific activated T-cells. The company has two diagnostic kits on the market based on their proprietary platform. T-TRACK CMV for the HLA-independent detection of CMV-specific cell-mediated immunity, and T-TRACK IMMUNOSCAN to check immune response due to natural, induced immunomodulation, In addition, Lophius also provides services and T-cell-based research tools for researchers and biopharma companies.
- Headquarters Regensburg, Germany
- Employees 28
- SectorsHealthcare
- Website lophius.com
- Social LinkedIn
- Legal Name Lophius Biosciences Gmbh
- Net Profit-$2.75 M (USD)-20as on Dec 31, 2019
- Total Equity Funding$23.73M (USD)
in 9 rounds
- Latest Funding Round$3.43M (USD), Series B
Sep 2019
- InvestorsEuropean Union
& 6 more
- Employee Count28
Funding Insights of Lophius Biosciences
Lophius Biosciences has successfully raised a total of $23.73M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $3.43 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.73M
- Total Rounds 9
- Last Round Series B — $3.43M
- First Round $845,364
(Oct 2008)
- Investors Count 7
All 9 funding rounds of Lophius Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $3.43M | Series B | – | VRD | – |
| Mar 2017 | $7.87M | Series B | – | VRD | |
| Jul 2016 | $4.67M | Series A | – | VRD | |
| Feb 2016 | $54,478 | Grant | – | – | |
| May 2014 | $2.75M | Series A | – | VRD | |
| Jul 2011 | $1.98M | Seed | – | Bayern Kapital, S REFIT | – |
| May 2010 | $2.2M | Seed | – | S REFIT | |
| Mar 2010 | $338,125 | Grant | – | – | – |
| Oct 2008 | $845,364 | Seed | – | Bayern Kapital, HTGF | – |
7 investors in total: 7 institutional.
Investors in Lophius Biosciences
Lophius Biosciences has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, VRD and Bayern Kapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment partnerships are provided by a family office for wealth growth. | vrd-investment.com | |||
High-tech industries are targeted for investments by Bayern Kapital. | bayernkapital.de | Landshut, Germany | ||
| s-refit.de | ||||
Early-stage investments are made in high-tech startups by HTGF. | htgf.de | Bonn, Germany | ||
Residential and commercial properties are leased in Chemnitz. | wic.de | Chemnitz, Germany | ||
Provides biological pest control, taubenabwehr, and integrated pest management services. | biotecwolf.de | Hamburg, Germany | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Lophius Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lophius Biosciences
3 dated milestones of Lophius Biosciences across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Lophius Biosciences is founded.
- Funding First funding round of $845K.
- Funding Latest funding round, Series B, of $3.4M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lophius Biosciences
Complete news archive for Lophius Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lophius Biosciences
Lophius Biosciences was founded in 2008.
Lophius Biosciences is headquartered in Regensburg, Germany. It is registered at Regensburg, Bavaria, Germany.
Lophius Biosciences is a funded company, having raised a total of $23.73M across 9 funding rounds to date. The company's 1st funding round was a Seed of $845.36K, raised on Oct 2008.
Lophius Biosciences has 28 employees.
Develops T-cell-based diagnostics for infectious and immune diseases. It has two proprietary platforms, T-activation Technology which allows the detection of clinically relevant effector cells such as T helper, NK, NKT-like, and CTL cells,and Reverse T cell Technology (RTT) which detects pathogen-specific activated T-cells. The company has two diagnostic kits on the market based on their proprietary platform. T-TRACK CMV for the HLA-independent detection of CMV-specific cell-mediated immunity, and T-TRACK IMMUNOSCAN to check immune response due to natural, induced immunomodulation, In addition, Lophius also provides services and T-cell-based research tools for researchers and biopharma companies.
Lophius Biosciences has 7 investors. Key investors include European Union, VRD, Bayern Kapital, Wohnen in Chemnitz, and BIOTEC KW WOLF.
Lophius Biosciences operates through Lophius Biosciences Gmbh.